Objective: To The prevalence of 25 hydroxyvitamin D [25(OH)D] deficiency, defined as 25(OH)D level less than 20 ng/mL, is high, especially among the elderly, with 25% to 65% affected. [1] [2] [3] [4] [5] [6] While much research has focused on the adverse effect of 25(OH)D deficiency on bone health, 5, 7 associations between 25(OH)D deficiency and non-bone health outcomes, including hypertension, 8 cardiovascular morbidity, 9 diabetes, 10,11 and cancer, 12,13 have also been reported. In addition, there is a growing body of literature to support the role of vitamin D in brain function and development.
pothesis are scarce. Cross-sectional studies that examined the association between 25(OH)D levels and cognition were limited by small sample size, 26 -28 did not control for potential confounding factors, 28 had suboptimal analytic methods to measure 25(OH)D levels, 6,26 -31 or reported conflicting results. 30 To our knowledge, there are no prospective cohort studies examining the association between 25(OH)D level and cognitive decline.
To test the hypothesis that lower 25(OH)D levels are associated with a greater likelihood of cognitive impairment and risk of cognitive decline, we measured 25(OH)D and assessed cognitive function using the Modified MiniMental State Examination (3MS) and Trail Making Test Part B (Trails B) in a cohort of 1,604 community-dwelling men aged 65 years or older who were enrolled in the Osteoporotic Fractures in Men (MrOS) Study and followed them prospectively for an average of 4.6 years for changes in cognitive function.
METHODS Participants. The MrOS Study is a multi-
center, prospective study of risk factors for vertebral and nonvertebral fractures in older men. The design, measures, and recruitment methods have been described previously. 32, 33 Briefly, 5,995 men aged 65 years or older were recruited from March 2000 to April 2002 from the populations of Birmingham, Alabama; Minneapolis, Minnesota; the Monongahela Valley, near Pittsburgh, Pennsylvania; Palo Alto, California; Portland, Oregon; and San Diego, California.
Men were excluded from the study if they could not walk without assistance, had bilateral hip replacements, did not live in or planned to move from the area surrounding the study site, or had a severe medical condition that would preclude participation in follow-up. Serum 25(OH)D measurements were obtained on specimens collected from a random sample of 1,606 participants at baseline examination. Of these, 1,604 participants (99.9%) had cognitive testing with 3MS, and of those, 1,564 participants (97.5%) had cognitive testing with Trails B at baseline examination and were included in the analyses examining the crosssectional association between 25(OH)D level and odds of cognitive impairment. An average (SD) of 4.6 (0.4) years later, 1,376 men (96.6% of survivors) participated in a second visit including 196 men who completed a mailed questionnaire only and 1,180 men who also attended a second clinic examination during which they underwent cognitive testing.
Standard protocol approvals, registrations, and patient consents. Approval was obtained from the institutional review boards of the participating institutions, and written informed consent was obtained from all study participants.
Vitamin D assays.
Fasting morning blood was collected, and serum was prepared immediately after phlebotomy and then stored at Ϫ70°C. All samples remained frozen until assay. Measures for 25(OH)D 2 (ergocalciferol) and 25(OH)D 3 (cholecalciferol) were performed at the Mayo Clinic using mass spectrometry as previously described. 34 Deuterated stable isotope (d3-25-hydroxyvitamin D) was added to a 0.2-mL serum sample as internal standard. 25(OH)D 2 , 25(OH)D 3 , and the internal standard were extracted using acetonitrile precipitation. The extracts were then further purified online and analyzed by liquid chromatography-tandem mass spectrometry using multiple reaction monitoring. 25(OH)D 2 and 25(OH)D 3 were quantified and reported individually. The minimum detectable limit was 4 ng/mL for 25(OH)D 2 and 2 ng/mL for 25(OH)D 3 . Duplicate pooled serum controls were included in every other assay run. Using the pooled serum, the interassay coefficient of variation (between assays) was 4.4% and the intra-assay coefficient of variation (within assay) was 4.9%. Total 25(OH)D was calculated by adding the 25(OH)D 2 and 25(OH)D 3 values. We used quartiles of the total vitamin D as the primary predictor. Because exposure to sunlight was expected to influence vitamin D levels, all analyses were adjusted for season and latitude of clinic site. Season of baseline visit was coded as winter (January-March), spring (April-June), summer (July-September), and fall (October-December).
Cognitive testing. Cognitive function was assessed by a trained technician with the 3MS (primary outcome) and Trails B (secondary outcome) at baseline and at the follow-up examination. The 3MS is a test of global cognitive function, with scores ranging from 0 to 100, with higher scores representing better cognitive function. 35 Trails B is a test of executive function. It assesses attention, concentration, psychomotor speed, cognitive shifting, and complex sequencing function by measuring the time required to connect a series of sequentially numbered and lettered circles. Shorter completion times indicate better performance, with test scores affected by age, education, and general intelligence. 36 For cross-sectional analyses, prevalent cognitive impairment was defined as having a baseline 3MS score Ͻ80 37 or a Trails B time greater than 1.5 SD above the mean (Ͼ226.5 seconds). For prospective analyses, incident cognitive impairment was defined as having a 3MS score Ͻ80 or a decline of 5 points or more 37 on the follow-up 3MS (approximately 1 SD change), or having a change in Trails B completion time that was 1 SD or more above the sample's mean change in completion time for those without prevalent impairment at baseline (Ͼ50.7 seconds), between the baseline and follow-up examinations. Men with prevalent cognitive impairment at baseline, as defined by a given cognitive test, were excluded from longitudinal analyses examining the association between 25(OH)D level and risk of cognitive decline as defined by that test.
Other measures. Demographic characteristics included age, education, and race. Lifestyle factors included alcohol consumption, smoking history, and physical activity (Physical Activity Scale for the Elderly [PASE] score). 38 Medical history included self-reported comorbid conditions. Diabetes was determined by combining data on self-report, medication usage, and fasting blood glucose. The number of selected medical conditions was calculated, which included history of cardiovascular disease (myocardial infarction, congestive heart failure, angina), diabetes, stroke, hypertension, and chronic obstructive pulmonary disease. Quality-of-life measures included self-rated health and the 12-Item Short Form Health Survey mental component summary (MCS) score. 39 Functional status was assessed from information on 5 instrumental activities of daily living (IADLs), which included walking 2 to 3 blocks on level ground, climbing 10 steps, preparing meals, doing heavy housework, and shopping for groceries or clothing. 40 Physical measures performed included height (stadiometer) and weight (balance beam or digital scale). 41 Height and weight were used to calculate body mass index (BMI) as weight in kilograms divided by the square of height in meters. Participants in the lower quartiles of vitamin D level were older, had higher BMI, were less likely to be white, were less likely to report excellent or good health, were more likely to report IADL impairments, and had a lower physical activity level (table 1) .
Statistical analysis. Differences in baseline characteristics

25(OH)D levels and baseline cognitive impairment.
Fifty-five men (3.4%) were classified as "impaired" at baseline based on having a 3MS score Ͻ80, and 145 men (9.3%) were classified as impaired at baseline based on time to completion of Trails B greater than 226.5 seconds. In all, 179 men were classified as impaired by at least 1 of the definitions. Of these, 124 were classified as impaired by the Trials B criteria but not by the 3MS criteria, 22 were classified as impaired by the 3MS criteria but not by the Trails B criteria, 21 were classified as impaired by both criteria, and 12 were classified as impaired according to the 3MS but were missing data on Trails B.
In After excluding those who did not complete follow-up cognitive testing and those who were impaired at baseline by a given test (23 [2.0%] by 3MS and 60 [5.4%] by Trails B), 1,138 men by the 3MS and 1,053 men by the Trails B were included in analyses of incident cognitive decline. Two hundred sixty men (22.8%) had developed incident cognitive impairment at follow-up based on 3MS score Ͻ80 or decline of Ն5 points, and 84 men (8.0%) developed incident cognitive impairment as defined by the change in time to completion of Trails B Ͼ50.7 seconds.
In models adjusted for age, season, and site, there was evidence of an association between lower 25(OH)D levels and odds of incident cognitive de- The only study 28 that found a correlation between lower vitamin D levels and performance on the 3MS was a small retrospective chart review, and no adjustment for other covariates was performed. In a study conducted in elders receiving home health services, correlation between 25(OH)D and Mini-Mental State Examination score (a measure of global cognitive function) approached significance, whereas the correlation between 25(OH)D and tests assessing executive function (Trails A and B, digit symbol coding, digit span, and matrix reasoning) was significant after adjustment for confounders. 6 A European study conducted in elderly men revealed an association between 25(OH)D and performance on the Digit Symbol Substitution Test, which measures psychomotor speed and visual scanning. 29 Conflicting results from the Third National Health and Nutrition Examination Survey study reported that psychometric measures were not associated with 25(OH)D level in the adolescent and adult groups, and elderly participants aged 60 years or older in the highest 25(OH)D quintile had the worst performance on a learning and memory task ( p ϭ 0.02) after adjustment for age, sex, race/ethnicity, and activity. 30 A study that examined an association between 25(OH)D level and mood disorder and cognition 31 found an association between 25(OH)D level Ͻ20 ng/mL with an active mood disorder, as well as poor performance on the Short Blessed Test and higher Clinical Dementia Rating score, after adjustment for age, race, gender, and season of vitamin D determination, but no association with performance on the 3MS. Another case-control study of subjects with secondary hyperparathyroidism without kidney disease found an association between secondary hyperparathyroidism and poor performance on 3 cognitive tests that tested working memory capacity, speed of information processing, and language compared with normal controls, whereas lower levels of vitamin D were not associated with cognitive performance. 26 Although there was an association between lower vitamin D levels and incident cognitive decline by the 3MS, its magnitude was somewhat attenuated by adjustment for age, site, and season of blood draw, and it no longer reached the level of significance after further covariate adjustment. Because the finding was of borderline significance, further large prospective studies are needed to test this hypothesis.
The study had a number of strengths, including prospective design, comprehensive measures of the cohort baseline characteristics, and analytical method used to quantify 25(OH)D level, but it also had several limitations. The participants were mostly healthy, white, elderly, community-dwelling men; therefore, the findings might not be generalizable to other populations. Because there was a trend for a higher risk of cognitive decline as assessed by the 3MS, the study might have been underpowered to detect an association because of healthy participant population and low prevalence of cognitive impairment. The excluded participants who did not have cognitive testing or did not participate in the follow-up were older, were frailer, and had lower baseline vitamin D levels and cognitive function, leaving healthy men in the cohort. Because a validated measure of depressive symptoms was not available at baseline, we did not include this factor in the multivariate models. Although widely accepted measures of cognition in older people were used, no uniform definition of cognitive impairment or decline exists for Trails B testing. For example, because there was no Trails A measurement, we are unable to discern whether worsening Trails B performance indicates worsening executive function or slower performance.
We did not find an independent association between vitamin D level and cognitive performance in the cohort of community-dwelling elderly men at baseline. There was a trend for an association between lower 25OH(D) level and decline in global cognitive function as measured by performance on the 3MS. Further studies that include women and a more comprehensive battery of neuropsychiatric testing are needed to further evaluate whether vitamin D deficiency is an independent determinant of agerelated changes in cognitive function.
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